Wednesday, July 01, 2015 7:38:48 PM
The company is doing it's job and I have no complaints about management. My last complaint/concern was with SPA not being taken to next level after CRL...but then the company appropriately filed First Amendment suit. Looking back on the documents Amarin had preview to, they clearly where in the right not wasting time with further SPA appeals...the FDA's rational is so off only a Judicial blow will course correct IMO.
I'm honest about my fear the stock may have been damaged beyond repair after 10-16, $500 million of market share left 10-17 with all faith destroyed in Regulatory scheme. If I crashed my previous plane would you fly with me? Your knowledge of the trade is far beyond mine, but how do we regain the faith of Wall Street to value AMRN after the FDA's done such a masterful job of crushing it's full potential value that can NEVER be recovered. (without judicial relief)
My political endeavors are going strong with my Senator sending me an update letter late last week.
Half the crap I'm doing now I can't/won't post...
My credibility? Since February 2013 I called it as I saw it...FDA was violating antitrust laws. I have publicly stated this and signed my name to it. I have discussed this with FDA on phone and numerous emails. No one supported this crazy theory, except me.
2013 Oct 17th I was contacted by Zum....EPADI was formed...had awesome leadership...I bowed out for two reasons 1) Family 2) IMO Group didn't understand the FDA's intent to kill Amarin and Vascepa
Also contacted by more than one HF manager...
Formulated a theory of FDA operating like a Cartel....Read a full RICO text book
Got a cease and desist from text book author who was perfectly willing to engage in 'Talk' but not action.
Contacted Senator filed SF95, claiming FDA was participating in Antitrust behavior that amounted to a cartel and should be prosecuted under RICO act.
Filed FOIA......this solidified Senate relationship as the FDA today has "prioritized" my request "waved fees", formed me it would be another 24 to 36 months (two weeks ago). Clearly they stonewall for a reason.
In developing the understanding with my Senator, I had contact with Senate Legal and Ethic Committee Attorneys...they are fully aware of my original SF95 complaint, EPADI CP and all censored posts, and that I hold all Congress and Senators to their fully sworn Oath to protect the Constitution. A fairly hollow argument coming from a commoner...until Amarin filed First Amendment suit against FDA.
I don't need "credibility"...
The individuals in the Government I deal with can see the body of my complaints and when I made them. I don't care what anyone else thinks..period!!! My goal is to stop the FDA from harming individuals by acting like common thugs..period
BB
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM